![Danaher Corporation Strengthens Diagnostics Offerings with $4B Acquisition of Cepheid](https://evolution-bio.com/wp-content/uploads/2016/09/160907-danaher-cepheid-bio.jpg)
Danaher Corporation has announced the acquisition of medical diagnostics company Cepheid, strengthening their presence in the Molecular Diagnostics market. Danaher will pay $53 per share in cash, a premium of
2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Bioscience
![2016 US Venture Capital Investment into Life Sciences Companies: An Analysis by Evolution Bioscience](https://evolution-bio.com/wp-content/uploads/2016/08/160802-vc-investment-evobio.jpg)
In order to elucidate the focus of Venture Capital funding in the Biotechnology sector this year, Evolution Analysts have assessed the deals carried out by the Top 25 US Venture
![M&A Analysis: Bio-Techne enters Genomics market with $250M acquisition of Advanced Cell Diagnostics](https://evolution-bio.com/wp-content/uploads/2016/07/160711-biotechne-acd-biosci.jpg)
Bio-Techne Corporation have agreed to acquire California-based molecular pathology company Advanced Cell Diagnostics for $250 million in cash plus additional potential milestone payments of up to $75M. The acquisition marks